Bendamustine: A review of pharmacology, clinical use and immunological effects (Review)
- Authors:
- Hrvoje Lalic
- Igor Aurer
- Drago Batinic
- Dora Visnjic
- Tomislav Smoljo
- Antonija Babic
-
Affiliations: Laboratory of Cell Biology and Croatian Institute for Brain Research, University of Zagreb School of Medicine, 10 000 Zagreb, Croatia, Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, 10 000 Zagreb, Croatia, Department of Physiology, University of Zagreb School of Medicine, 10 000 Zagreb, Croatia, Department of Laboratory Immunology, Clinical Department of Laboratory Diagnostics, University Hospital Center Zagreb, 10 000 Zagreb, Croatia - Published online on: May 3, 2022 https://doi.org/10.3892/or.2022.8325
- Article Number: 114
-
Copyright: © Lalic et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
WHO collaborating centre for drug statistics methodology, . ATC classification index with DDDs. Oslo, Norway: 2021 | |
|
Cheson BD and Rummel MJ: Bendamustine: Rebirth of an Old Drug. J Clin Oncol. 27:1492–1501. 2009. View Article : Google Scholar | |
|
Cheson BD and Leoni L: Bendamustine: Mechanism of action and clinical data. Clin Adv Hematol Oncol. 9 (8 Suppl 19):S1–S11. 2011. | |
|
World Health Organization model list of essential medicines, 21st list 2019, . Geneva: World Health Organization; 2019 | |
|
Gandhi V and Burger JA: Bendamustine in B-cell malignancies: The new 46-year-old kid on the block. Clin Cancer Res. 15:7456–7461. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Garnock-Jones KP: Bendamustine: A review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Drugs. 70:1703–1718. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tageja N: Bendamustine: Safety and efficacy in the management of indolent non-hodgkins lymphoma. Clin Med Insights Oncol. 5:145–156. 2011. View Article : Google Scholar | |
|
Hoy SM: Bendamustine: A review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma. Drugs. 72:1929–1950. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fu D, Calvo JA and Samson LD: Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 12:104–120. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G and Niemeyer CC: Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 14:309–317. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Leoni LM and Hartley JA: Mechanism of action: The unique pattern of bendamustine-induced cytotoxicity. Semin Hematol. 48 (Suppl 1):S12–S23. 2011. View Article : Google Scholar | |
|
Leoni LM: Bendamustine: Rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol. 48 (Suppl 1):S4–S11. 2011. View Article : Google Scholar | |
|
Hiraoka N, Kikuchi J, Yamauchi T, Koyama D, Wada T, Uesawa M, Akutsu M, Mori S, Nakamura Y, Ueda T, et al: Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies. PLoS One. 9:e906752014. View Article : Google Scholar : PubMed/NCBI | |
|
Arimany-Nardi C, Montraveta A, Lee-Vergés E, Puente XS, Koepsell H, Campo E, Colomer D and Pastor-Anglada M: Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells. Pharmacogenomics J. 15:363–371. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hagos Y, Hundertmark P, Shnitsar V, Marada VV, Wulf G and Burckhardt G: Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake. Am J Physiol Physiol. 308:F330–F338. 2015. View Article : Google Scholar | |
|
Schwänen C, Hecker T, Hübinger G, Wölfle M, Rittgen W, Bergmann L and Karakas T: In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia. 16:2096–2105. 2002. View Article : Google Scholar | |
|
Matthews HK, Bertoli C and de Bruin RAM: Cell cycle control in cancer. Nat Rev Mol Cell Biol. 23:74–88. 2022. View Article : Google Scholar | |
|
Vitale I, Galluzzi L, Castedo M and Kroemer G: Mitotic catastrophe: A mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 12:385–392. 2011. View Article : Google Scholar | |
|
Cai B, Lyu H, Huang J, Wang S, Lee CK, Gao C and Liu B: Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. Cancer Lett. 335:343–350. 2013. View Article : Google Scholar | |
|
Cai B, Wang S, Huang J, Lee CK, Gao C and Liu B: Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. Am J Transl Res. 5:36–46. 2013.PubMed/NCBI | |
|
Visco C, Castegnaro S, Chieregato K, Bernardi M, Albiero E, Zanon C, Madeo D and Rodeghiero F: The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis. 48:68–75. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gaul L, Mandl-Weber S, Baumann P, Emmerich B and Schmidmaier R: Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: The role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol. 134:245–253. 2008. View Article : Google Scholar | |
|
Kaneko N, Mitsuoka K, Amino N, Yamanaka K, Kita A, Mori M, Miyoshi S and Kuromitsu S: Combination of YM155, a survivin suppressant, with bendamustine and rituximab: A new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma. Clin Cancer Res. 20:1814–1822. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Beeharry N, Rattner JB, Bellacosa A, Smith MR and Yen TJ: Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine. PLoS One. 7:e403422012. View Article : Google Scholar : PubMed/NCBI | |
|
Darwish M, Bond M, Hellriegel E, Robertson P Jr and Chovan JP: Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 75:1143–1154. 2015. View Article : Google Scholar | |
|
Dubbelman AC, Rosing H, Darwish M, D'Andrea D, Bond M, Hellriegel E, Robertson P Jr, Beijnen JH and Schellens JH: Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy. Drugs R D. 13:17–28. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kim T, Choi HY, Lee HS, Jung SH, Ahn JS, Kim HJ, Lee JJ, Yoo HD and Yang DH: Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). BMC Cancer. 18:7292018. View Article : Google Scholar : PubMed/NCBI | |
|
Cephalon Inc., . Treanda (bendamustine hydrochloride for injection) for intravenous infusion. US prescribing information. 2021. | |
|
Knauf WU, Lissitchkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, et al: Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: Updated results of a randomized phase III trial. Br J Haematol. 159:67–77. 2012. View Article : Google Scholar | |
|
Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, et al: First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 17:928–942. 2016. View Article : Google Scholar | |
|
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, et al: Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 379:2517–2528. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, de la Serna J, et al: ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 38:2849–2861. 2020. View Article : Google Scholar | |
|
Fraser GAM, Chanan-Khan A, Demirkan F, Santucci Silva R, Grosicki S, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Loscertales J, et al: Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 61:3188–3197. 2020. View Article : Google Scholar | |
|
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, et al: Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 378:1107–1120. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, et al: Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 377:1331–1344. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, et al: Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety. J Clin Oncol. 36:2395–2404. 2018. View Article : Google Scholar | |
|
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, et al: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 381:1203–1210. 2013. View Article : Google Scholar | |
|
Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, et al: First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: Results of the BRIGHT 5-year follow-up study. J Clin Oncol. 37:984–991. 2019. View Article : Google Scholar | |
|
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, et al: Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 17:1081–1093. 2016. View Article : Google Scholar | |
|
Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, et al: Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 36:2259–2266. 2018. View Article : Google Scholar | |
|
Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, et al: Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: A multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 17:57–66. 2016. View Article : Google Scholar | |
|
Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, et al: Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: A multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 4:e15–e23. 2017. View Article : Google Scholar | |
|
McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL, Quaglia FM, McMillan A, Lambert J, Crosbie N and Rule S: Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 189:684–688. 2020. View Article : Google Scholar | |
|
Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, et al: Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Adv. 3:3132–3135. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, et al: A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol. 175:281–289. 2016. View Article : Google Scholar | |
|
Flinn IW, Erter J, Daniel DB, Mace JR and Berdeja JG: Phase II study of bendamustine and ofatumumab in elderly patients with newly diagnosed diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy. Oncologist. 24:1035–e623. 2019. View Article : Google Scholar | |
|
Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, Kim TM, McMillan A, Ozcan M, Safar V, et al: Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort data. Blood Adv. 6:533–543. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, et al: Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: An international, multicentre, single-arm, phase 1–2 trial. Lancet Oncol. 19:257–266. 2018. View Article : Google Scholar | |
|
Broccoli A, Argnani L, Botto B, Corradini P, Pinto A, Re A, Vitolo U, Fanti S, Stefoni V and Zinzani PL; Fondazione Italiana Linfomi ONLUS, : First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: A phase 2 study of the Fondazione Italiana Linfomi. Blood Cancer J. 9:1002019. View Article : Google Scholar : PubMed/NCBI | |
|
LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, et al: Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. Br J Haematol. 189:e86–e90. 2020. View Article : Google Scholar | |
|
Hueso T, Gastinne T, Garciaz S, Tchernonog E, Delette C, Casasnovas RO, Durot E, Houot R, Tessoulin B, Tournilhac O, et al: Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: A multicenter retrospective study from lymphoma study association (LYSA) centers. Bone Marrow Transplant. 55:1076–1084. 2020. View Article : Google Scholar | |
|
Gomez-Arteaga A, Mark TM, Guarneri D, Christos PJ, Gergis U, Greenberg JD, Hsu J, Mayer SA, Niesvizky R, Pearse RN, et al: High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 54:2027–2038. 2019. View Article : Google Scholar | |
|
Lee HC, Feng L, Oriabure O, Graham V, Chen W, Badillo M, Lu R, Lee HJ, Jain P, Manasanch EE, et al: A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol. 96:E243–E246. 2021. View Article : Google Scholar | |
|
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, et al: Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study. Lancet Oncol. 17:200–211. 2016. View Article : Google Scholar | |
|
Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, et al: Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 33:969–980. 2019. View Article : Google Scholar | |
|
Cheson BD, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, Ogura M, Weidmann E, Wendtner CM and Zinzani PL: Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel-an update. Leuk Lymphoma. 57:766–782. 2016. View Article : Google Scholar | |
|
Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, et al: Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study. Blood. 123:2944–2952. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, et al: Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. Br J Haematol. 178:250–256. 2017. View Article : Google Scholar | |
|
Fung M, Jacobsen E, Freedman A, Prestes D, Farmakiotis D, Gu X, Nguyen PL and Koo S: Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine. Clin Infect Dis. 68:247–255. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pezzullo L, Giudice V, Serio B, Fontana R, Guariglia R, Martorelli MC, Ferrara I, Mettivier L, Bruno A, Bianco R, et al: Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens. Open Med (Wars). 16:672–682. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, et al: RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: Results of SWOG study S1106. Br J Haematol. 176:759–769. 2017. View Article : Google Scholar | |
|
Smith A, Roman E, Appleton S, Howell D, Johnson R, Burton C and Patmore R: Impact of novel therapies for mantle cell lymphoma in the real world setting: A report from the UK's haematological malignancy research network (HMRN). Br J Haematol. 181:215–228. 2018. View Article : Google Scholar | |
|
Bašić-Kinda S, Mišura Jakobac K, Sinčić-Petričević J, Deak D, Vodanović M, Jakić-Bubalo M, Mitrović Z, Grubešić A, Dreta B, Županić Krmek D, et al: Improvement in the outcomes of mantle cell lymphoma in the last decade: A real-life non interventional study of the croatian cooperative group for hematologic diseases. Croat Med J. 62:455–463. 2021. View Article : Google Scholar | |
|
Roué G, López-Guerra M, Milpied P, Pérez-Galán P, Villamor N, Montserrat E, Campo E and Colomer D: Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res. 14:6907–6915. 2008. View Article : Google Scholar | |
|
Aurer I: Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation. Curr Opin Oncol. 31:374–379. 2019. View Article : Google Scholar | |
|
Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G, Thorns C, Hartmann S, Kluin-Nelemans H, Hermine O, et al: Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL network. Blood. 131:417–420. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma. 2019. | |
|
Nikitorowicz-Buniak J: CHMP recommends EMA approval of polatuzumab vedotin for the treatment of adult patients with R/R DLBCL. 2019. | |
|
Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, Noy A, Palomba ML, Portlock CS, Straus DJ, et al: Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 31:456–460. 2013. View Article : Google Scholar | |
|
Rinnerthaler G, Gampenrieder SP, Petzer A, Hubalek M, Petru E, Sandholzer M, Andel J, Balic M, Melchardt T, Hauser-Kronberger C, et al: Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Results of a phase II trial (AGMT MBC-6). Ther Adv Med Oncol. 13:175883592110423012021. View Article : Google Scholar | |
|
Lammers PE, Shyr Y, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL and Horn L: Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol. 9:559–562. 2014. View Article : Google Scholar | |
|
Hartmann JT, Mayer F, Schleicher J, Horger M, Huober J, Meisinger I, Pintoffl J, Käfer G, Kanz L and Grünwald V; German sarcoma group, : Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: A noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer. 110:861–866. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chambers SK: Open trial of bendamustine hydrochloride in women with advanced ovarian cancer. NCT00867503. 2012. | |
|
Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, et al: Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol. 26:204–210. 2008. View Article : Google Scholar | |
|
Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, et al: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 27:4378–4384. 2009. View Article : Google Scholar | |
|
Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH and Tremmel L: Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 10:452–457. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Stokes J, Molina MS, Hoffman EA, Simpson RJ and Katsanis E: Immunomodulatory effects of bendamustine in hematopoietic cell transplantation. Cancers (Basel). 13:17022021. View Article : Google Scholar : PubMed/NCBI | |
|
Allegra A, Tonacci A, Musolino C, Pioggia G and Gangemi S: Secondary immunodeficiency in hematological malignancies: Focus on multiple myeloma and chronic lymphocytic leukemia. Front Immunol. 12:7389152021. View Article : Google Scholar | |
|
Gafter-Gvili A, Gurion R, Raanani P, Shpilberg O and Vidal L: Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials. Hematol Oncol. 35:424–431. 2017. View Article : Google Scholar | |
|
Lamure S, Duléry R, Di Blasi R, Chauchet A, Laureana C, Deau-Fischer B, Drenou B, Soussain C, Rossi C, Noël N, et al: Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. EClinicalMedicine. 27:1005492020. View Article : Google Scholar : PubMed/NCBI | |
|
Fraser C, Brown P, Megason G, Ahn HS, Cho B, Kirov I, Frankel L, Aplenc R, Bensen-Kennedy D, Munteanu M, et al: Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: Efficacy and tolerability. J Pediatr Hematol Oncol. 36:e212–e218. 2014. View Article : Google Scholar | |
|
García Muñoz R, Izquierdo-Gil A, Muñoz A, Roldan-Galiacho V, Rabasa P and Panizo C: Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol. 93:1879–1887. 2014. View Article : Google Scholar | |
|
Saito H, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto K, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y, et al: Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J. 5:e3622015. View Article : Google Scholar : PubMed/NCBI | |
|
Coutre SE, Flinn IW, de Vos S, Barrientos JC, Schreeder MT, Wagner-Johnson ND, Sharman JP, Boyd TE, Fowler N, Dreiling L, et al: Idelalisib in combination with rituximab or bendamustine or both in patients with relapsed/refractory chronic lymphocytic leukemia. Hemasphere. 2:e392018. View Article : Google Scholar : PubMed/NCBI | |
|
Rummel MJ, Janssens A, MacDonald D, Keating MM, Zaucha JM, Davis J, Lasher J, Babanrao Pisal C, Izquierdo M and Friedberg JW: A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study). Br J Haematol. 193:1123–1133. 2021. View Article : Google Scholar | |
|
Schöffski P, Seeland G, Engel H, Grünwald V, Paul H, Merkle K, Kowalski R and Ganser A: Weekly administration of bendamustine: A phase I study in patients with advanced progressive solid tumours. Ann Oncol. 11:729–734. 2000. View Article : Google Scholar | |
|
Bremer K: High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol. 128:603–609. 2002. View Article : Google Scholar | |
|
Klippstein A, Schneider CP, Sayer HG and Höffken K: Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol. 129:316–319. 2003. View Article : Google Scholar | |
|
Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, et al: Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol. 71:1183–1190. 2013. View Article : Google Scholar | |
|
Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W and Kreitman RJ: Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res. 19:6313–6321. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Martínez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H, Balotis C, Kennedy B, Wagner S, Dyer MJS, et al: Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: A population-based analysis. Br J Haematol. 184:957–968. 2019. | |
|
Stokes J, Hoffman EA, Zeng Y, Larmonier N and Katsanis E: Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation. Br J Haematol. 174:102–116. 2016. View Article : Google Scholar | |
|
Cona A, Tesoro D, Chiamenti M, Merlini E, Ferrari D, Marti A, Codecà C, Ancona G, Tincati C, d'Arminio Monforte A and Marchetti G: Disseminated cytomegalovirus disease after bendamustine: A case report and analysis of circulating B- and T-cell subsets. BMC Infect Dis. 19:8812019. View Article : Google Scholar : PubMed/NCBI | |
|
Stokes J, Hoffman EA, Molina MS, Kummet N, Simpson RJ, Zeng Y and Katsanis E: Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia. Oncoimmunology. 9:17580112020. View Article : Google Scholar : PubMed/NCBI | |
|
García M, Bellosillo B, Sánchez-González B, García-Payarols F, Seoane A, Ferrer AM, Gimeno E, Barranco LE, Torner A, Solé F, et al: Study of regulatory T-cells in patients with gastric malt lymphoma: Influence on treatment response and outcome. PLoS One. 7:e516812012. View Article : Google Scholar | |
|
Molina MS, Hoffman EA, Stokes J, Kummet N, Smith KA, Baker F, Zúñiga TM, Simpson RJ and Katsanis E: Regulatory dendritic cells induced by bendamustine are associated with enhanced Flt3 expression and alloreactive T-cell death. Front Immunol. 12:6991282021. View Article : Google Scholar | |
|
Lepik KV, Mikhailova NB, Kondakova EV, Zalyalov YR, Fedorova LV, Tsvetkova LA, Kotselyabina PV, Borzenkova ES, Babenko EV, Popova MO, et al: A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed/refractory Hodgkin lymphoma after nivolumab monotherapy failure. Hemasphere. 4:e4012020. View Article : Google Scholar : PubMed/NCBI | |
|
Montraveta A, Lee-Vergés E, Roldán J, Jiménez L, Cabezas S, Clot G, Pinyol M, Xargay-Torrent S, Rosich L, Arimany-Nardí C, et al: CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. Oncotarget. 7:5507–5520. 2016. View Article : Google Scholar | |
|
Gafter-Gvili A and Polliack A: Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 57:512–519. 2016. View Article : Google Scholar | |
|
Yamasaki S, Matsushima T, Minami M, Kadowaki M, Takase K and Iwasaki H: Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: A single-institute retrospective study. Ann Hematol. 101:209–211. 2022. View Article : Google Scholar | |
|
Lu L, Yoshimoto K, Morita A, Kameda H and Takeuchi T: Bendamustine increases interleukin-10 secretion from B cells via p38 MAP kinase activation. Int Immunopharmacol. 39:273–279. 2016. View Article : Google Scholar | |
|
Stenger EO, Turnquist HR, Mapara MY and Thomson AW: Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood. 119:5088–5103. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Barbarroja-Escudero J, Sanchez-Gonzalez MJ, Antolin-Amerigo D, Rodriguez-Rodriguez M and Alvarez-Mon M: Hypersensitivity reactions and drug fever by bendamustine: A case report of three patients. Allergol Int. 64:109–111. 2015. View Article : Google Scholar | |
|
Chan M, Silverstein WK, Nikonova A, Pavenski K and Hicks LK: Bendamustine-induced immune hemolytic anemia: A case report and systematic review of the literature. Blood Adv. 4:1756–1759. 2020. View Article : Google Scholar : PubMed/NCBI |
